Price alert —
Sign in to get a one-time email the moment PCSA crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · PCSA
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-12-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-09-30 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-06-30 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-03-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare PCSA vs peers
Line PCSA up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with PCSA
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2025-11-06 | -1.75 | -2.00 | +12.5% | -3.2% |
| 2025-08-07 | -6.25 | -5.75 | -8.7% | +0.4% |
| 2025-05-08 | -7.50 | -19.25 | +61.0% | -12.8% |
| 2025-03-20 | -18.50 | -23.00 | +19.6% | +1.2% |
| 2024-10-30 | -25.75 | -25.00 | -3.0% | -13.2% |
| 2024-08-13 | -25.25 | -24.50 | -3.1% | -0.7% |
| 2024-05-10 | -27.75 | -29.50 | +5.9% | +6.2% |
| 2024-03-29 | -203.50 | -40.00 | -408.8% | -0.6% |
| 2023-11-13 | -40.00 | -50.00 | +20.0% | +8.7% |
| 2023-08-10 | -50.00 | -75.00 | +33.3% | +7.8% |
| 2023-05-15 | -90.00 | -140.00 | +35.7% | -8.2% |
| 2023-03-30 | -175.00 | -152.50 | -14.8% | +4.2% |
| 2022-11-08 | -185.00 | -167.50 | -10.4% | -4.7% |
| 2022-08-11 | -160.00 | -95.00 | -68.4% | +2.4% |
| 2022-05-12 | -100.00 | -106.67 | +6.2% | -7.2% |
| 2022-03-30 | -105.00 | -100.00 | -5.0% | -3.2% |
| 2021-11-12 | -95.00 | -92.50 | -2.7% | -7.2% |
| 2021-08-12 | -100.00 | -70.00 | -42.9% | -7.5% |
| 2021-05-13 | -70.00 | -55.00 | -27.3% | — |
| 2021-03-25 | -850.00 | -177.50 | -378.9% | — |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| PCSA ★ | $0B | — | -0.6 | — | -0.3 | 2.4 | — | — | — | -108.82% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 6.42%
| Holder | Shares | % out |
|---|---|---|
| Connective Capital Management LLC | 70,736 | 2.56% |
| Stonepine Capital Management, LLC | 55,000 | 1.99% |
| Geode Capital Management, LLC | 24,908 | 0.90% |
| Vanguard Capital Management LLC | 12,729 | 0.46% |
| Vanguard Fiduciary Trust Co | 10,857 | 0.39% |
| UBS Group AG | 2,531 | 0.09% |
| Tower Research Capital LLC (TRC) | 918 | 0.03% |
| Citigroup Inc. | 14 | — |
| Jones Financial Companies, L.L.L.P. | 7 | — |
| Wells Fargo & Company | 6 | — |
Insider activity · 90d
15 buys / 0 sells · ratio 15.0 · Finnhub
- Ng George K BUY 15,492 @ $1.93
- Guy Wendy BUY 14,394 @ $1.93
- Lin Patrick BUY 13,113 @ $1.93
- Young David BUY 21,729 @ $1.93
- SKIBSTED RUSSELL BUY 16,689 @ $1.93
- Ng George K BUY 12,435 @ $2.22
- Lin Patrick BUY 11,007 @ $2.22
- Guy Wendy BUY 11,958 @ $2.22
- Young David BUY 19,198 @ $2.22
- SKIBSTED RUSSELL BUY 13,412 @ $2.22
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-07-01 | FORM 4 | view · |
| 4 | 2026-07-01 | FORM 4 | view · |
| 4 | 2026-07-01 | FORM 4 | view · |
| 4 | 2026-07-01 | FORM 4 | view · |
| 4 | 2026-07-01 | FORM 4 | view · |
| 4 | 2026-06-30 | FORM 4 | view · |
| 4 | 2026-06-30 | FORM 4 | view · |
| 4 | 2026-06-30 | FORM 4 | view · |
| 4 | 2026-06-30 | FORM 4 | view · |
| DEF 14A | 2026-06-18 | DEF 14A | view · |
| 4 | 2026-06-16 | FORM 4 | view · |
| 4 | 2026-06-16 | FORM 4 | view · |
| 4 | 2026-06-16 | FORM 4 | view · |
| 4 | 2026-06-16 | FORM 4 | view · |
| 4 | 2026-06-16 | FORM 4 | view · |
| 4 | 2026-06-01 | FORM 4 | view · |
| 4 | 2026-06-01 | FORM 4 | view · |
| 4 | 2026-06-01 | FORM 4 | view · |
| 4 | 2026-06-01 | FORM 4 | view · |
| 4 | 2026-06-01 | FORM 4 | view · |
| 4 | 2026-05-19 | FORM 4 | view · |
| 4 | 2026-05-19 | FORM 4 | view · |
| 4 | 2026-05-19 | FORM 4 | view · |
| 4 | 2026-05-19 | FORM 4 | view · |
| 4 | 2026-05-19 | FORM 4 | view · |
| 10-Q | 2026-05-07 | 10-Q | view · |
| 4 | 2026-05-01 | FORM 4 | view · |
| 4 | 2026-05-01 | FORM 4 | view · |
| 4 | 2026-05-01 | FORM 4 | view · |
| 4 | 2026-05-01 | FORM 4 | view · |
| 4 | 2026-05-01 | FORM 4 | view · |
| 4 | 2026-05-01 | FORM 4 | view · |
| 8-K | 2026-04-30 | 8-K | view · |
| 4 | 2026-04-17 | FORM 4 | view · |
| 4 | 2026-04-17 | FORM 4 | view · |
| 4 | 2026-04-17 | FORM 4 | view · |
| 4 | 2026-04-17 | FORM 4 | view · |
| 4 | 2026-04-17 | FORM 4 | view · |
| 4 | 2026-04-17 | FORM 4 | view · |
| 4 | 2026-04-02 | FORM 4 | view · |
| 4 | 2026-04-01 | FORM 4 | view · |
| 4 | 2026-04-01 | FORM 4 | view · |
| 4 | 2026-04-01 | FORM 4 | view · |
| 4 | 2026-04-01 | FORM 4 | view · |
| 4 | 2026-04-01 | FORM 4 | view · |
| 4 | 2026-04-01 | FORM 4 | view · |
| 4 | 2026-04-01 | FORM 4 | view · |
| 4 | 2026-04-01 | FORM 4 | view · |
| 10-K | 2026-03-18 | 10-K | view · |
| 8-K | 2026-02-19 | 8-K | view · |
| 4 | 2026-02-04 | FORM 4 | view · |
| 4 | 2026-02-04 | FORM 4 | view · |
| 4 | 2026-02-04 | FORM 4 | view · |
| 4 | 2026-02-04 | FORM 4 | view · |
| 8-K | 2026-01-07 | 8-K | view · |
| 8-K | 2025-12-15 | 8-K | view · |
| 10-Q | 2025-11-06 | 10-Q | view · |
| 4 | 2025-10-03 | Insider transaction (Form 4) | view · |
| 4 | 2025-10-03 | Insider transaction (Form 4) | view · |
| 4 | 2025-10-03 | Insider transaction (Form 4) | view · |
About PCSA
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly spe…
Options picks · PCSA
ITM + OTM ideas from the latest scanLoading…
Congress trades · PCSA
STOCK Act disclosuresLoading…
SEC filings & insiders · PCSA
EDGAR · liveLoading…
Holders · PCSA
Institutions & insider activityLoading…